USS Investment Management Ltd lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 8.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 126,927 shares of the medical research company’s stock after acquiring an additional 9,504 shares during the quarter. USS Investment Management Ltd’s holdings in Edwards Lifesciences were worth $10,165,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in EW. Level Four Advisory Services LLC increased its stake in shares of Edwards Lifesciences by 3.7% in the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after purchasing an additional 119 shares in the last quarter. Evermay Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 4.0% in the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock worth $282,000 after acquiring an additional 128 shares during the period. Rehmann Capital Advisory Group boosted its holdings in shares of Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after acquiring an additional 130 shares during the period. Florida Trust Wealth Management Co grew its position in shares of Edwards Lifesciences by 1.5% in the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock valued at $751,000 after purchasing an additional 132 shares in the last quarter. Finally, McIlrath & Eck LLC grew its position in shares of Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Stock Performance
Edwards Lifesciences stock opened at $91.95 on Thursday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $92.88. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The stock has a market cap of $52.95 billion, a P/E ratio of 48.91, a price-to-earnings-growth ratio of 2.27 and a beta of 0.85. The firm’s fifty day moving average price is $85.06 and its 200-day moving average price is $83.41.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on EW. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a report on Wednesday, April 1st. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Finally, Barclays reiterated an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $96.39.
Insider Buying and Selling at Edwards Lifesciences
In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 58,977 shares of company stock worth $4,921,803 in the last 90 days. 0.31% of the stock is owned by company insiders.
Edwards Lifesciences Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More
- Five stocks we like better than Edwards Lifesciences
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
